Novavax is a biotechnology company promoting improved global health through the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including both its coronavirus vaccine candidate, (NVX-CoV2373) and its nanoparticle seasonal quadrivalent influenza vaccine candidate (NanoFlu), are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Co.'s technology may be used to target a variety of infectious diseases. Co.'s technology is paired with its proprietary immune stimulating adjuvants, developed at Novavax AB, its wholly owned Swedish subsidiary. We show 52 historical shares outstanding datapoints in our coverage of NVAX's shares outstanding history.
Understanding the changing numbers of NVAX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like NVAX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching NVAX by allowing them to research NVAX shares outstanding history
as well as any other stock in our coverage universe. |
Free NVAX Email Alerts:
Video: Shares Outstanding Importance
